ʜB, MD,‡ Daren M. Beam, MD,#
Michael W. Ardagh, MB, CʜB, DCʜ, PʜD,† Richard Troughton, MB, CʜB, PʜD,*†
Anthony F. T. Brown, MB, CʜB,‡¤ Peter George, MB, BS,* Christopher M. Florkowski, MB, BS,*
Jeffrey A. Kline, MD,# W. Frank Peacock, MD,** Alan S. Maisel, MD,†† Swee Han Lim, MB, BS,‡‡
Arvin Lamanna, MB, BS,‡ A. Mark Richards, MD, PʜD†

Christchurch, New Zealand; Brisbane and Melbourne, Australia; Charlotte, North Carolina; Cleveland, Ohio, San Diego, California; and Singapore

Objectives

Methods

Results

Patient characteristics.

The results show that the ADP is sensitive for both early and late presenters, identifying a greater proportion of patients as low risk in early presenters. Thus, the ADP could have the greatest impact in patients presenting within 3 h of symptom onset, the group in which the second troponin sampling time point is usually most delayed.

Body et al. (21) described how a highly sensitive cTn (HS-cTn) assay may allow early “rule-out” of AMI using a